Omega Fund Management, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Omega Fund Management, LLC reported 10 stock positions worth $185.7 million. Its top holding was Bicara Therapeutics (BCAX) at 29.1% of the portfolio, followed by Nuvation Bio (NUVB, 24.7%) and Kestra Medical Technologies (KMTS, 14.0%). Compared with Q1 2026, it opened 1 new position, sold out of 1 and reduced 1. The biggest buy was a new position in Odyssey Therapeutics (ODTX) and the biggest sale an exit from Replimune (REPL).
- Most Recent 13F
- Q2 2026
- Location
- Boston, MA
- CIK
- 0001637359
- Portfolio Value
- $185.7M (Q2 2026)
- SEC Filing
- 0001193125-26-350681 ↗ filed Aug 14, 2026
Holdings Value
Holdings 10 stocks · $185.7M
| BCAX Bicara Therapeutics Inc. | 29.14% | 1,822,150 | $54.1M | Reduce -23.8% |
| NUVB Nuvation Bio Inc. | 24.72% | 8,081,089 | $45.9M | No change |
| KMTS Kestra Medical Technologies | 14.00% | 1,022,149 | $26.0M | No change |
| BBOT Bridgebio Oncology Therapeut | 13.50% | 3,289,661 | $25.1M | No change |
| BBNX Beta Bionics Inc. | 11.11% | 1,316,183 | $20.6M | No change |
| ALMS Alumis Inc. | 3.66% | 241,255 | $6.8M | No change |
| SANA Sana Biotechnology Inc. | 1.59% | 843,750 | $2.9M | No change |
| IMA Imagenebio Inc. | 1.45% | 455,361 | $2.7M | No change |
| ENGN Engene Holdings Inc. | 0.82% | 876,357 | $1.5M | No change |
| ODTX Odyssey Therapeutics Inc. | 0.03% | 2,893 | $54K | New |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
| ODTX Odyssey Therapeutics Inc. | New | 0.03% | +0.03 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $185.7M | BCAX, NUVB, KMTS, BBOT, BBNX |
| Q1 2026 | 10 | $163.1M | BCAX, NUVB, BBOT, KMTS, BBNX |
| Q4 2025 | 11 | $286.5M | NUVB, BBOT, BBNX, BCAX, KMTS |
| Q3 2025 | 12 | $222.4M | KMTS, BBNX, BBOT, BCAX, NUVB |
| Q2 2025 | 13 | $154.4M | BBNX, KMTS, UPB, NUVB, BCAX |
| Q1 2025 | 13 | $169.5M | KMTS, BCAX, BBNX, NUVB, REPL |
| Q4 2024Amended | 12 | $154.2M | BCAX, NUVB, UPB, REPL, LXEO |
| Q3 2024 | 11 | $160.0M | BCAX, NUVB, REPL, LXEO, ENGN |
| Q2 2024 | 11 | $135.0M | NUVB, LXEO, REPL, ENGN, ALMS |
| Q1 2024 | 11 | $155.0M | NUVB, LXEO, REPL, ENGN, SANA |